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INTRODUCTION
Tumor necrosis factor-alpha blocking agents are important 
and effective options in the treatment of several chronic 
inflammatory arthropathies (CIAs), especially rheumatoid 
arthritis (RA), that present inadequate response to methotrexate 
and/or other disease-modifying drugs (DMARDS). On the 
other hand, they are also associated with a higher frequency 
of serious adverse events, especially infectious and allergic 
complications.
It is known that TNF is important for granuloma formation 
and maintenance, and, therefore, anti-TNF therapy might cause 
disorganization of granulomas and cause reactivation of latent 
granulomatous infections, such as tuberculosis and leprosy.
Pharmacological and biochemical peculiarities of anti-
TNFα agents can explain the differences among them, 
especially regarding safety.1,2 Monoclonal antibodies, chimeric 
(infliximab - IFX) or human (adalimumab - ADA), neutralize 
soluble TNF-a, as well as that bound to the cell membrane with 
more avidity and for a longer time, while etanercept (ETN) 
binds only the soluble fraction, in a more reversible way, and 
for a shorter time. Additionally, IFX and ADA promote more 
apoptosis, as well as a dose-dependent reduction in the levels 
of interferon gamma (IFN-γ) in a dose-dependent fashion. On 
the other hand, ETN lacks those characteristics. The reduction 
in the concentration of IFN-γ can also be associated with failure 
to inhibit the intracellular growth of mycobacteria.3,4
Mycobacterium leprae causes a chronic disease with 
two clinical presentations: tuberculoid leprosy, represented 
by well-organized granulomas with few mycobacteria; and 
lepromatous leprosy, characterized by less organized lesions 
and with a greater number if bacilli. The clinical presentation 
is polymorphic, ranging from skin changes, with areas of 
desensitization and hypopigmentation, to more severe neural 
lesions or involvement of other organs, including bones and 
joints.
CASE REPORT
A.T.S., a 44 year-old male patient had had a diagnosis of RA 
for five years, characterized by symmetrical polyarthritis of 
small and large joints, associated with prolonged morning 
stiffness, negative rheumatoid factor and anti-citrullinated 
peptide antibodies (APF – perinuclear antibody), as well as 
erosive radiological changes in hips and wrists. The patient 
was initially treated with methotrexate and corticosteroids, 
but, due to persistent articular activity and worsening 
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articular capacity (HAQ = 1.3), leflunomide was associated 
to the therapeutic regimen and, after failure of this combined 
therapy, IFX was instituted. He used methotrexate and IFX 
for 21 months with no reports of relevant adverse reactions, 
but maintaining moderate disease activity (DAS28 between 
3.6 and 5.4). As the response to chimeric anti-TNF remained 
inadequate, it was decided to substitute it by ADA. Fifteen 
days after the introduction of the new medication, the patient 
developed non-pruriginous, non-desquamative erythematous 
maculae disseminated in the trunk and extremities (Figure 1), 
associated with fever, myalgia, and thickening of the ulnar 
nerve. Skin biopsy confirmed the diagnosis of lepromatous 
leprosy, according to the classification of Ridley and Jopling, 
with a bacilliferous index of +2/+4 (Figure 2). Epidemiology 
was negative for leprosy. Anti-TNF therapy was discontinued 
and specific treatment for leprosy was instituted (clofazimine, 
rifampin, and dapsone), scheduled to last 24 months. After 12 
months of polychemotherapy, the patient showed improvement 
of the skin lesions, but remained with polyarticular activity 
(DAS28 = 6.4), even on high doses of corticosteroids (40 mg/
day of prednisone).
DISCUSSION
Anti-TNFα therapy is associated with a wide variety of common 
or opportunistic infections, in addition to other manifestations 
related to allergic or immunologic phenomena. The frequency 
of the association between anti-TNF blockers and adverse 
cutaneous reactions diverge among the different studies.
Wallis et al., studying the data in the reports of adverse 
events of the FDA (Food Drug Administration), observed an 
incidence of granulomatous disease of 238.6 and 73.5/100 
thousand patients treated with IFX and ETN, respectively, 
during almost five years of observation. Among mycobacterial 
infections, the majority was caused by Mycobacterium 
tuberculosis (60.2%, for IFX, and 46.9%, for ETN), followed 
by other species (5.4%, for IFX, and 8.4%, for ETN). 
Mycobacterium leprae was identified as the causative agent 
in only 0.1%, all in the IFX group.2
Figure 1
Erythematous maculae, with little desquamation, 
disseminated in the trunk.
Figure 2
A: Perivascular lymphomononuclear infiltrate.
Non-epithelioid differentiated macrophages. Abundant 
cytoplasm with opacified vacuoli. vacuolvacuolesacificados. 
B: Bacilli within the vacuoli. Ziehl Nielsen staining positive 
for intracytoplasmic acid-fast bacilli.
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In the United States, two patients with RA who developed 
lepromatous leprosy 12 and 24 months after the onset of 
treatment with IFX have been reported.5 Recently, Oberstein 
et al. reported on a patient from the Amazon region with 
symmetrical polyarthritis and inadequate response to 
corticosteroids and MTX, who developed diffuse macular rash 
with biopsy compatible with tuberculoid leprosy after using 
ADA.6 Our patient was treated with IFX for almost two years 
and he did not develop significant adverse reaction, but, two 
weeks after it was substituted for ADA, he developed cutaneous 
lesions characteristic of lepromatous leprosy. It is known that 
the natural history of leprosy is characterized by a slow course 
until the development of skin lesions; however, in this case, 
an intimate temporal correlation between the modification of 
the anti-TNF agent and the cutaneous lesion was observed. 
It is not possible to state with certainty whether changing the 
anti-TNF agent was responsible for triggering the disease or 
whether the patient had a latent infection and the change in the 
medication was only a temporal coincidence.
Once again, the immunogenic characteristics of TNF 
blockers (chimeric monoclonal versus human, for instance) 
can explain the reason for the late cutaneous manifestation of 
leprosy. Thus, since IFX is chimeric in nature and, consequently, 
more immunogenic, one could suppose that the presence of 
more human anti-chimera antibodies (HACAs) with potentially 
less concentration of the agent in the leprosy microenvironment 
would neutralize? the granuloma disorganization. Changing 
to a human agent might have led to greater TNF blockade, as 
this agent is not neutralized by anti-IFX antibodies or HACAs. 
These aspects (changing the anti-TNF agent and clinical type 
of leprosy) make this case unique.
Musculoskeletal manifestation can develop during leprosy 
reactions7 and can mimic CIAs, which might delay the correct 
diagnosis. In leprosy, the involved joints are similar to those 
observed in RA (wrists, metacarpophalangeal, proximal 
interphalangeal, metatarsophalangeal, knees), associated 
with morning stiffness.8 Rheumatoid factor can be present in 
these patients,9 although, more recently, Ribeiro et al. have 
demonstrated a low prevalence of this autoantibody and anti-
citrullinated peptides (anti-CCP) among us.10
The exact mechanism by which TNFα blockers cause the 
reactivation of latent granulomatous infections is not well 
known, but it has been speculated that disorganization of 
the granuloma would be directly related to TNF and to the 
imbalance between the production and the release of IFNγ and 
IFNa, as well as the complex interaction among circulating 
lymphocytes and epithelioid cells and local macrophages 
(innate and acquired immunity). Munk et al. demonstrated that 
elevated plasma concentrations of the soluble TNFα receptor 
I in leprosy patients could cause ineffective regulation of 
the inflammatory activity by inhibiting the in vitro cytolytic 
activity of TNF. This finding suggests that the regulatory 
activity of the soluble TNF receptor is partially hindered in 
patients with lepromatous leprosy, but not in other clinical 
types of the disease.11
In the three cases reported in the literature,5,6 the differential 
diagnosis between RA and leprosy-related arthritis remained 
uncertain. On the other hand, in the case reported here, the 
patient had erosive and symmetrical polyarthritis of small 
and large joints five years before the development of leprosy, 
developing severe ankylosis of hips and shoulders, articular 
findings that are not observed in leprosy patients. These 
particularities can help to attain the differential diagnosis 
between the musculoskeletal manifestations of leprosy and 
RA. It is important to stress that, in general, the articular 
involvement improves after the treatment of leprosy, which 
was not observed in the case presented here.
CONCLUSION
Anti-TNFα therapy has been long and widely used in the 
treatment of patients with different CIAs who present 
inadequate response to methotrexate and other DMARDS. 
However, the risks should be weighted and discussed with 
the patient, especially the reactivation of latent granulomatous 
infections, such as tuberculosis and leprosy, which are endemic 
in Brazil. Thus, a wide, adequate, and careful evaluation before 
starting the therapy with TNFα blockers is recommended to 
minimize adverse reactions. Moreover, more attention should 
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